Spyre Therapeutics, LLC

Spyre Therapeutics has dosed the first participant in a Phase 1 trial of SPY003, a half-life extended IL-23 antibody designed for potential quarterly or biannual dosing in inflammatory bowel disease patients.

Spyre Therapeutics' SPY001 demonstrates a >90-day half-life in Phase 1 trials, suggesting potential for quarterly or bi-annual subcutaneous maintenance dosing in IBD.

Spyre Therapeutics reports positive interim results from its Phase 1 trial of SPY001, a novel half-life extended anti-α4β7 antibody.

Spyre Therapeutics is progressing its SPY001 program, an anti-a4ß7 monoclonal antibody, with interim Phase I data expected by year-end for IBD treatment.

Spyre Therapeutics anticipates initiating first-in-human dosing of SPY003, a novel half-life extended anti-IL-23 monoclonal antibody, in Q1 2025, with interim data expected in the second half of 2025.